Biotechnology Company

BioViva USA, Inc.

8%

Funding Goal $15,000,000
Funding Raised So Far $1,200,000
Funding Commitments $0
Funding Remaining $13,800,000
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Company Overview

Gene and cell therapy company that treats diseases and aging at the cellular level... with a potential solution to Alzheimer's Disease, Sarcopenia, Atherosclerosis and some cancers. Human clinical trials are scheduled.

We are committed to creating regenerative medicine to alleviate diseases caused by cellular degeneration and genetic disorders. We focus on aging, as this is the common root of most major diseases.

We bring these treatments to network clinics for both compassionate and consensual use and to change how we treat disease in the future.

lock icon

Invest in Company

Sign up or log in now to unlock profile details and access financials, company documents, and invest in companies.

Investor Sign Up
Investor Log In

Business Summary

Company Age
Employees
Sub-Industry
Prior Year Revenue
Current Year Revenue
Next Year Revenue

Products/Services

Gene therapies for major aging-related disease and conditions

BioViva offers potential single treatment cures and vaccines for sarcopenia, atherosclerosis, Alzheimer's Disease and cancer and will begin human clinical trials in 2018.

Gene therapy

Aging is a complex process that inevitably leads to disease and dysfunction, and this is why we are targeting our therapies at aging... to head disease off at the pass. These are some of our immediate targets to develop gene therapies for, and this will develop as we develop new ways to treat illness and learn more about aging:

* Lengthen Telomeres
* Reverse Atherosclerosis
* Clear Misfolded Proteins
* Clear Senescent Cells
* Re-strengthen Muscles
* Re-boot the immune System
* Improve Cell Signaling
* Treat Monogenic Disease

Management

Elizabeth Parrish
Chief Executive Officer
Elizabeth P......

Ms. P...... is a humanitarian, entrepreneur and innovator, is a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of regenerative medicine modalities, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach and sits on the board of the International Longevity Alliance (ILA). She is an affiliated member of the Complex Biological Systems Alliance (CBSA), which is a unique platform for mensa based, highly gifted persons who advance scientific discourse and discovery. The mission of the CBSA is to further scientific understanding of biological complexity and the nature and origins of human disease. She is also the Secretary of The American Longevity Alliance (ALA) a 501(c)(3) nonprofit trade association that brings together individuals, companies, and organizations who work in advancing the emerging field of cellular & regenerative medicine.

Jason Williams, M.D.
Chief Physician/Medical Officer
Jason W......

Dr. Williams is a radiologist with a passion for gene and cellular therapies that can be administered under image guidance. He also has an interest in image guided cancer therapies. He did research for several years with adenoviral vector technology for the treatment of cancer. He has spent the last 5 years involved in research using AAV technology. Dr. Williams obtained his medical degree from Louisiana State University and completed an internship in Internal Medicine followed by a residency in Radiology at The University Of South Alabama. In residency, he was selected for the RSNA Research Fellow award. He is board certified by The American Board of Radiology with additional training in image guided cancer and spine procedures. His research interest is in gene therapy and reprogramming of stem cells. He also has research interest in the use of CT and MRI guidance for minimally invasive procedures related to the spine and treatment of cancer.

David A. Kekich
Director Strategic Planning
David A......

Mr. is a recognized authority on longevity science. In 1999, he founded "Maximum Life Foundation", a 501(c)(3) not-for-profit corporation dedicated to reversing human aging and aging related diseases. Since then, the Foundation, in concert with many of the world’s leading researchers, has developed a scientific roadmap to transform the elderly to biological youth.

David first became intrigued with extreme life extension in 1977 after founding the country's largest life insurance master general agency, which raised $3.1 billion of premium income for First Executive Corp. This was where he was widely exposed to the realities and horrors of death from aging.

Currently, he also serves as CEO of Age Reversal, Inc. and Board Member Life Extension Buyers’ Club..He was a Board Member of the American Aging Assoc and Alcor Life Extension Foundation Patient Care Trust Fund for many years. He authored “Smart, Strong and Sexy at 100, a how-to book for extreme life extension.

Avi Roy
Chief Technology Officer
Avi R......

Pres. Biogerontology Research Foundation, a UK-based charity for ageing research. Oxford based scientist with degrees in both biomedical & computer science. His PhD research rejuvenates human skin and identifies accurate aging biomarkers. Rejuvenated 80 year old patient skin cells by transplanting mitochondria from 16 y/o skin cells. Using transcriptomics, proteomics and computational biology, he identified pathways to rejuvenate skin. Screens small molecules to replicate regenerative process. His research resulted in advanced protocol to screen drugs with properties that I.D.'d 12 novel geroprotective drugs.

Over past 10 years, Avi headed the Oxford Univ. Scientific Society, world’s oldest student scientific organization. Co-founded Oxford Univ. Synthetic Biology Society and others. Organized >370 talks, chaired 8 conferences and hosted 28 Nobel prize winners. Launched Big Data Science in Medicine Conference series & the Longevity Reporter, premier source of health & longevity news

8%

Funding Goal $15,000,000
Funding Raised So Far $1,200,000
Funding Commitments $0
Funding Remaining $13,800,000
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Documents

Contact

BioViva USA, Inc.

Bainbridge Island, WA 98110, US

Top 10 Tips for Entrepreneurs Seeking Funding

Users who follow these tips increase their fundraising odds substantially.

  • Complete Your Funding Profile
    • Complete your funding profile with all sections filled, including your products and services, a complete management team with headshots, and slideshow with product images.
  • Complete a Business Plan (Optional)
    • Complete a Business Plan in EquityNet and refine your financial projections using the benchmarking alerts in the Business Plan Analysis report.
  • Upload Important Investment Documents
    • Upload and present any other important investment documents such as pitch decks, financial statements, and offering materials.
  • Use EquityNet Crowdcast
    • Use the EquityNet Crowdcast system to automatically email invitations to your contacts in order to build additional exposure for your company.
  • Construct Concise Introductory Messages
    • Construct and send a concise introductory message to investors, including primary reasons why they should want to invest such as KPIs, expected returns, and forecasted revenue.
  • Be Proactive in Messaging Investors
    • Be proactive in messaging many investors and include a simple way for them to connect with you for a web meeting or call, such as a Calendly link.
  • Use the Activity System
    • Use the Activity system to track interested investors, and send prompt follow-up messages to investors who viewed your profile or showed interest.
  • Prepare for Due Diligence
    • Prepare for due diligence questions by interested investors and use your Business Plan and investment documents to satisfy such requests.
  • Keep Your Funding Profile Updated
    • Keep your funding profile updated with new funding raised/committed and message interested investors with any new milestones achieved.
  • Do Not Respond to Unknown Investors
    • Do not respond to or engage any parties outside of EquityNet that are not listed as approved investors (this may happen due to your public profile and LinkedIn connections).